CD28 and cancer: Consistently with the above results, comparing the effect of Pep3 pretreatment followed by 4 days of anti-CD3/CD28 stimulation in PBMC of TC cancer patients versus a small cohort of healthy donors (HD), no differences were observed in the analyzed cell subsets (Figure S4).